Andrew S Huhn

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 18

Top Venues

Experimental and clinical psychopharmacology

The American journal on addictions

Sleep

Brain and behavior

Johns Hopkins University School of Medicine

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Johns Hopkins University School of Medicine Jun 05 2016

United States

Assistant Professor :: Psychiatry and Behavioral Sciences

Publications

Matthew J Reid, Kelly E Dunn, Liza Abraham, Jennifer Danielle Ellis, Carly Hunt, Charlene E Gamaldo, William G Coon, Chung Jung Mun, Eric C Strain, Michael T Smith, Patrick H Finan, Andrew S Huhn
Suvorexant alters dynamics of the sleep-electroencephalography-power spectrum and depressive-symptom trajectories during inpatient opioid withdrawal. Sleep 47 (4) (2024)
Jennifer D Ellis, Daniel Han, Jami Mayo, J Gregory Hobelmann, Patrick H Finan, Andrew S Huhn
The association of pain impact and sleep disruption with opioid withdrawal during opioid-use disorder treatment. British journal of clinical pharmacology (2024)
Matthew J Reid, Kelly E Dunn, Liza Abraham, Jennifer Danielle Ellis, Carly Hunt, Charlene E Gamaldo, William G Coon, Chung Jung Mun, Eric C Strain, Michael T Smith, Patrick H Finan, Andrew S Huhn
Suvorexant alters dynamics of the sleep-electroencephalography-power spectrum and depressive-symptom trajectories during inpatient opioid withdrawal. Sleep 47 (4) (2024)
Matthew J Reid, Kelly E Dunn, Liza Abraham, Jennifer Danielle Ellis, Carly Hunt, Charlene E Gamaldo, William G Coon, Chung Jung Mun, Eric C Strain, Michael T Smith, Patrick H Finan, Andrew S Huhn
Suvorexant alters dynamics of the sleep-EEG power spectrum and depressive symptom trajectories during inpatient opioid withdrawal. Sleep (2024)
Matthew J Reid, Kelly E Dunn, Liza Abraham, Jennifer Danielle Ellis, Carly Hunt, Charlene E Gamaldo, William G Coon, Chung Jung Mun, Eric C Strain, Michael T Smith, Patrick H Finan, Andrew S Huhn
Suvorexant alters dynamics of the sleep-electroencephalography-power spectrum and depressive-symptom trajectories during inpatient opioid withdrawal. Sleep 47 (4) (2024)
Jennifer D Ellis, Daniel Han, Jami Mayo, J Gregory Hobelmann, Patrick H Finan, Andrew S Huhn
The association of pain impact and sleep disruption with opioid withdrawal during opioid-use disorder treatment. British journal of clinical pharmacology 90 (6) (2024)
Andrew S Huhn, Jennifer Danielle Ellis
Promoting Sleep Health to Mitigate the Risk of Non-medical Opioid Use and Opioid-related Adverse Events. Sleep (2023)
Andrew S Huhn, Patrick H Finan, Charlene E Gamaldo, Alexis S Hammond, Annie Umbricht, Cecilia L Bergeria, Eric C Strain, Kelly E Dunn
Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper. Science translational medicine 14 (650) (2022)
Neil B Varshneya, Kelly E Dunn, Caitlyn J Grubb, Sandra I Okobi, Andrew S Huhn, Cecilia L Bergeria
Can initial experiences with drugs predict future drug abuse risks? Experimental and clinical psychopharmacology (2022)
Cecilia L Bergeria, Hongjun Tan, Denis G Antoine, Elise M Weerts, Andrew S Huhn, J Gregory Hobelmann, Kelly E Dunn
A double-blind, randomized, placebo-controlled, pilot clinical trial examining buspirone as an adjunctive medication during buprenorphine-assisted supervised opioid withdrawal. Experimental and clinical psychopharmacology (2022)
Andrew S Huhn, Jennifer Danielle Ellis
Commentary on Zolopa et al.: Trauma as an impediment to successful aging and a precipitant of opioid and stimulant use among older adults. Addiction (Abingdon, England) 117 (8) (2022)
Jennifer Danielle Ellis, Jami L Mayo, Patrick H Finan, Charlene E Gamaldo, Andrew S Huhn
Clinical correlates of drug-related dreams in opioid use disorder. The American journal on addictions (2021)
Joseph Gregory Hobelmann, Andrew S Huhn
Comprehensive pain management as a frontline treatment to address the opioid crisis. Brain and behavior 11 (11) (2021)
Andrew S Huhn, Cassandra D Gipson
Promoting harm reduction as a treatment outcome in substance use disorders. Experimental and clinical psychopharmacology 29 (3) (2021)
Andrew S Huhn, Patrick H Finan
Sleep disturbance as a therapeutic target to improve opioid use disorder treatment. Experimental and clinical psychopharmacology (2021)
Denis Antoine, Andrew S Huhn, Eric C Strain, Gavin Turner, Jasmyne Jardot, Alexis S Hammond, Kelly E Dunn
Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone. The American journal on addictions 30 (1) (2020)
Andrew S Huhn, Kelly E Dunn
Challenges for Women Entering Treatment for Opioid Use Disorder. Current psychiatry reports 22 (12) (2020)
Andrew S Huhn, Meredith S Berry, Kelly E Dunn
Review: Sex-Based Differences in Treatment Outcomes for Persons With Opioid Use Disorder. The American journal on addictions 28 (4) (2019)

Andrew S Huhn.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Andrew S Huhn